ACM
MPLT

ADAR1 Capital Management’s MapLight Therapeutics MPLT Stock Holding History

ADAR1 Capital Management’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$950K Sell
26,497
-348,412
-93% -$10M 0.04% 173
2026
Q1 		$7.62M Buy
+374,909
New +$6.71M 0.45% 53

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NFGH
Nan Fung Group Holdings Kai Tak, Hong Kong $131M AUM 86.64% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ADAR1 Capital Management's MPLT Position: Q2 2026 in Review

ADAR1 Capital Management reduced its MapLight Therapeutics (MPLT) stake by 93% in Q2 2026, selling an estimated $10M and leaving 26,497 shares worth $950K. The position accounts for 0.04% of the portfolio, ranked #173.

ADAR1 Capital Management first reported a position in MPLT in Q1 2026 and has held it in 2 quarters since. The position peaked at $7.62M in Q1 2026. 106 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • ADAR1 Capital Management held 26,497 shares of MapLight Therapeutics worth $950K as of Q2 2026.
  • ADAR1 Capital Management sold 348,412 MapLight Therapeutics shares in Q2 2026, an estimated $10M.
  • MapLight Therapeutics made up 0.04% of ADAR1 Capital Management's portfolio in Q2 2026, its #173 holding.
  • ADAR1 Capital Management first reported a position in MapLight Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • ADAR1 Capital Management's MapLight Therapeutics position peaked at $7.62M in Q1 2026.
  • 106 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on ADAR1 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.